Basso Capital Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-125,000
Closed -$45K 215
2017
Q3
$45K Hold
125,000
0.01% 157
2017
Q2
$48K Hold
125,000
0.01% 144
2017
Q1
$56K Sell
125,000
-25,000
-17% -$11K 0.01% 124
2016
Q4
$57K Sell
150,000
-25,000
-14% -$8.46K 0.01% 131
2016
Q3
$47K Sell
175,000
-100,000
-36% -$25.3K 0.01% 129
2016
Q2
$66K Sell
275,000
-95,000
-26% -$16.3K 0.01% 118
2016
Q1
$42K Hold
370,000
0.01% 134
2015
Q4
$42K Buy
370,000
+150,000
+68% +$21.2K 0.01% 129
2015
Q3
$42K Hold
220,000
0.01% 117
2015
Q2
$154K Sell
220,000
-25,000
-10% -$17.3K 0.02% 101
2015
Q1
$166K Buy
245,000
+20,000
+9% +$14K 0.02% 102
2014
Q4
$178K Sell
225,000
-50,000
-18% -$34.2K 0.03% 106
2014
Q3
$128K Hold
275,000
0.02% 99
2014
Q2
$138K Hold
275,000
0.02% 91
2014
Q1
$88K Buy
275,000
+55,000
+25% +$20.4K 0.02% 94
2013
Q4
$75K Buy
220,000
+110,000
+100% +$133K 0.01% 78
2013
Q3
$222K Hold
110,000
0.04% 79
2013
Q2
$212K Buy
+110,000
New +$193K 0.04% 83

Other funds holding GCVRZ

Basso Capital Management's GCVRZ Position: Q4 2017 in Review

Basso Capital Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2017, closing a stake of 125,000 shares — an estimated $45K sold.

Basso Capital Management first reported a position in GCVRZ in Q2 2013 and held it in 18 quarters. The position peaked at $222K in Q3 2013. 105 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2017.

  • Basso Capital Management reported no remaining Sanofi Contingent Value Rights position as of Q4 2017 after selling out during the quarter.
  • Basso Capital Management sold 125,000 Sanofi Contingent Value Rights shares in Q4 2017, an estimated $45K.
  • Basso Capital Management first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 18 quarters.
  • Basso Capital Management's Sanofi Contingent Value Rights position peaked at $222K in Q3 2013.
  • 105 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2017.

Based on Basso Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.